Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago.
Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings
AI is revolutionizing healthcare, with Recursion Pharmaceuticals leveraging AI and vast datasets for drug discovery, making it a compelling investment opportunity. Recursion's integrated drug discovery platform, partnerships with major pharma companies, and significant data resources, position it for growth despite current financial challenges. The FDA's shift towards AI-based models for preclinical drug development could provide Recursion with a strong tailwind, reducing costs and accelerating timelines.
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.84, denoting a +1.83% change from the preceding trading day.
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Artificial intelligence (AI) is changing the world. Corporations are racing to establish themselves as leaders in the field, while investors want to cash in by putting their hard-earned money into the most promising AI companies.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $6.48, denoting a -1.52% change from the preceding trading day.
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
Why Recursion Pharmaceuticals Stock Is Sinking Today
Shares of Recursion Pharmaceuticals (RXRX -5.54%) were sinking 8.2% lower as of 10:57 a.m. ET on Monday.
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
The artificial intelligence (AI) industry has been on a tear in the past two years, and judging by analyst estimates, it's just the beginning. AI-related sales will continue to soar in the coming years, so naturally, investors want to cash in by investing in those companies best positioned to profit from AI.
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (RXRX -5.17%).
This Biotech Stock Could Be the Best Investment of the Decade
It's typically not too difficult to find a company that should perform well for the next couple of years. Two years isn't very long, after all, and the stock market's dynamics tend to dictate performance more.
